Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients
Sponsor: Sandoz
Terminated
investigation of adverse events
Listed as NCT00701714, this PHASE3 trial focuses on Anemia and Chronic Renal Insufficiency and remains terminated or withdrawn. Sponsored by Sandoz, it has been updated 9 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE3
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Terminated PHASE3
-
Jan 2017 — Mar 2018 [monthly]
Terminated PHASE3
First recorded
Sep 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sandoz
For direct contact, visit the study record on ClinicalTrials.gov .